Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Special glasses may tame nearsightedness by reshaping the eye

NCT ID NCT07686289

Disease control Sponsor: Kubota Vision Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests whether special glasses called Kubota Glass can temporarily change the length of the eye, which is key to controlling nearsightedness (myopia). Participants aged 8 to 24 with mild to moderate myopia will try five different lens settings in a randomized, double-masked design. The goal is to find the best optical defocus parameters for slowing myopia progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Kubota Glass (optical defocus device)
What this could lead to
If successful, this could lead to a non-invasive way to slow or control myopia progression in children and young adults.
What could go wrong
This is a small, early-stage study focused on temporary changes, not long-term outcomes. The effect may not translate to lasting myopia control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 24 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be of legal age or, if under legal age have written consent of their parent or guardian to participate. * Sign written Informed Consent (and the California Bill of Rights, if applicable). * Be between age 8-24 (inclusive) and able to understand and assent to participation. * Have a spherical component of spectacle prescription between -1.00 and -5.00 diopters (D) (inclusive) in each eye. * Have a refractive astigmatism of less than or equal to -1.00 D in each eye. * Have axial length between 23.00 and 25.99 millimeters (mm) in each eye. * Best Spectacle Corrected Visual Acuity (BSCVA) of 20/25 or better in each eye. * Be willing and able to follow instructions and attend the schedule of follow-up visits. Exclusion Criteria: * Unable or unwilling to provide informed consent and assent. * Eye injury or surgery within twelve weeks immediately prior to enrollment. * Currently enrolled in an ophthalmic clinical trial. * Pregnant or lactating or expect to become pregnant during the trial (by self-report). * Evidence of systemic or ocular abnormality, infection or disease. * Use of medications that may affect the eye (including, but not limited to, corticosteroids and antimetabolites). * Anisometropia ≥ 2.00. * Subjects who have undergone corneal refractive surgery. * Use atropine or other anticholinergic drug within the past month. * Employees or immediate family members of employees of study sites or sponsor.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.